Business Context and Reporting Period
This Form 8-K filing by BridgeBio Pharma, Inc. (BBIO) reports a corporate governance event dated February 12, 2020. The company is a biopharmaceutical firm incorporated in Delaware and listed on the Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members effective February 12, 2020.
- New Appointment: Ronald J. Daniels was appointed as a Class III director, serving until the 2022 annual meeting of stockholders.
- Compensation Grant: Mr. Daniels received an option to purchase 91,554 shares of common stock at an exercise price of $34.65 per share.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the rationale for Mr. Daniels' appointment, citing his extensive experience as a professor and leader at Johns Hopkins University.
Investor Verification Checklist
- Verify the vesting schedule of the 91,554 stock options granted to Mr. Daniels (three equal annual installments).
- Confirm the closing market price of $34.65 on February 12, 2020, to validate the exercise price.
- Review the standard form of indemnification agreement filed as Exhibit 10.4 to Amendment No. 4 to the Form S-1.
- Check for any subsequent filings regarding Mr. Daniels' continued service or resignation.